News | June 24, 2024
Ascentage Pharma closes US$ 75 million equity investment by Takeda
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
